
Fermi Inc. Common Stock
Fermi Inc. Common Stock (FRMI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
frmi · stock forecast · 3 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Buy
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$11.00
Consensus
$8.33
+46.8% upside
Low
$6.00
Median: $8 · Last Close: $5.67
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$8.33
46.8% upside
High Target
$11
93.8%
Low Target
$6
5.7%
Current Price
$5.67
as of today
Based on analyst price targets, the FRMI stock price prediction for the next 12 months ranges from $6 to $11. The consensus FRMI price forecast of $8.33 implies 46.8% upside from the current price of $5.67.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $5.54 | ↓ 2.32% |
1-day model range: $5.45–$5.63. Peak: $5.63 (-2.32%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · FRMI · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Evercore ISI Group | Downgrade ↓ | Outperform→In Line |
| 2026-04-20 | Macquarie | Maintains | Outperform→Outperform |
| 2026-04-01 | UBS | Maintains | Buy→Buy |
| 2026-04-01 | Macquarie | Maintains | Outperform→Outperform |
| 2026-02-09 | Macquarie | Maintains | Outperform→Outperform |
| 2025-11-12 | Macquarie | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Fermi Inc. Common Stock (FRMI) stock. Of the recent 6 rating actions, 0 were upgrades and 1 were downgrades. 3 analysts currently cover FRMI.
Analyst Recommendation Trends
FRMI analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$74M
↓ 98.0% YoY
Revenue Next Year
$1.2B
↑ 1586.4% YoY
EPS This Year
$0.06
EPS Next Year
$0.76
↑ 1205.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast FRMI EPS of $0.06 for the current fiscal year, based on estimates from 3 analysts. The FRMI revenue forecast is $74M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The FRMI stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FRMI price target is $8.33 (+46.8% upside), with an analyst consensus of Buy.
The FRMI short-term stock prediction for tomorrow is $5.54 (-2.32%).
Fermi Inc. Common Stock trades on NASDAQ under the ticker FRMI. The FRMI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.
Frequently asked questions
FRMI forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month FRMI price target is $8.33, with a high forecast of $11.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +46.8% potential upside from the current price of $5.67.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.